Investment Banking Summer Analyst - Healthcare and Life Sciences

Viking Therapeutics has priced an upsized $500 million concurrent public offering of common stock and convertible senior notes. The clinical-stage biopharmaceutical company will sell 7,857,143 shares at $35.00 per share and $225 million in 2% convertible senior notes due 2032. The offering size was increased from the previously announced $200 million for each component. The notes carry an initial conversion price of approximately $50.75 per share, representing a 45% premium over the public offering price. Viking estimates net proceeds of approximately $258.2 million from the common stock offering and $218 million from the note offering, after deducting underwriting discounts and expenses. The company intends to use proceeds for continued clinical development of its VK2735 and VK3019 programmes, as well as general research and development purposes. Morgan Stanley, JPMorgan, Jefferies, Leerink Partners, and William Blair are serving as joint book-running managers.

Leerink Partners, a healthcare-focused investment bank, has appointed Chris McCarthy as senior managing director to strengthen its institutional equities platform. McCarthy will be based in New York and report to Rob Leerink, head of institutional equities. McCarthy brings over 25 years of experience serving institutional healthcare investors. He joins from RBC Capital Markets, where Institutional Investor ranked him the number one healthcare salesperson three times in the past five years. He previously held healthcare sales positions at Bank of America and Cowen. In his new role, McCarthy will work with Leerink's research, sales, trading, and capital markets teams to provide market insights and strategic advice to institutional investors.

Leerink Partners expands Institutional Equities platform with appointment of Chris McCarthy as Senior Managing Director. PR Newswire BOSTON, Aug. 24, 2026 /PRNewswire/ - Leerink Partners, a leading investment bank specializing in healthcare, today announced that Chris McCarthy has joined the Firm as a Senior Managing Director, further strengthening its Institutional Equities platform while expanding its healthcare sales capabilities. Mr. McCarthy will be based in Leerink Partners' New York office and will report to Rob Leerink, Head of Institutional Equities. Mr. McCarthy brings more than 25 years of experience serving institutional healthcare investors. He joins from RBC Capital Markets, where he was ranked the No. 1 Healthcare Salesperson by Institutional Investor three times over the past five years. Prior to RBC Capital Markets, he held healthcare sales roles at Bank of America and Cowen (now TD Cowen). "Chris is a highly respected healthcare sales professional who has earned an outstanding reputation across the industry through decades of building trusted relationships with investors. His market insight, client focus, and deep understanding of the healthcare landscape will help us expand our reach," said Rob Leerink. "He will leverage his industry expertise and market intelligence to support institutional investors and corporate clients as we continue investing in our leading institutional equities platform." In his role, Mr. McCarthy will collaborate closely with the Firm's research, sales, trading, and capital markets professionals to deliver differentiated market insights and strategic advice to institutional investors. "Leerink Partners has built the industry's premier healthcare investment banking and institutional equities platform, with a longstanding reputation for delivering differentiated insights and exceptional client service," said Mr. McCarthy. "I'm excited to join such a talented team and work alongside my colleagues to help clients navigate one of the most innovative and rapidly evolving periods in healthcare." About Leerink Partners LLC Leerink Partners LLC is a highly specialized healthcare investment bank with a legacy of excellence in the financial industry. The Firm's experienced team delivers innovative advisory solutions, capital raising expertise, and unique insights to empower clients to achieve their strategic objectives. Since inception the Firm has advised on $85 billion, helped clients raise over $225 billion, and has established itself as a trusted partner to healthcare companies and their investors. The Firm is a broker-dealer registered with the United States Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority.